BACKGROUND: Currently, the two main methods used to analyze human epidermal growth factor receptor 2 (HER2) amplification or overexpression have a limited accuracy and high costs. These limitations can be overcome by the development of complementary quantitative methods. METHODS: In this study, we analyzed HER2 mRNA expression in clinical formalin-fixed and paraffin-embedded (FFPE) samples using a one-tube nested reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay. We measured expression relative to 3 reference genes and compared the results to those obtained by conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays with 226 FFPE breast cancer tissue samples. RESULTS: The one-...
The assessment of ERa, PgR and HER2 status is routinely performed today to determine the endocrine r...
PURPOSE Decades of quality control efforts have raised the standards of immunohistochemistry (IHC...
Novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates have demonst...
Abstract Background Immunohistochemistry (IHC) and fluorescent-in situ hybridization (FISH) are stan...
Detection of human epidermal growth factor receptor 2 gene (HER2, also known as erbB2) expression is...
It seems that controversy is ever present regarding the optimal approach to testing for human epider...
The human epidermal growth factor receptor 2 gene (HER2) is amplified in approximately 15%–20% of al...
RATIONALE: Human epidermal growth factor receptor 2 (HER2) is a key driver of tumorigenesis, and ove...
Breast cancer patients who have a positive result for HER2 overexpression are commonly treated with ...
Knowledge of estrogen receptor (ER) and progesterone receptor (PR) status has been critical in the e...
Human epidermal growth factor receptor HER2/neu status is an important prognostic factor for breast ...
Over-expression of the human epidermal growth factor receptor-2 (HER2/neu) has been observed in many...
[[abstract]]Background: HER2 gene is amplified and/or overexpressed in approximate 15% to 20% of pri...
Objectives - Reliable assessment of estrogen, progesterone (ER and PR), and HER2 receptor status are...
Background: Optimization of workflow for breast cancer samples with equivocal human epidermal growth...
The assessment of ERa, PgR and HER2 status is routinely performed today to determine the endocrine r...
PURPOSE Decades of quality control efforts have raised the standards of immunohistochemistry (IHC...
Novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates have demonst...
Abstract Background Immunohistochemistry (IHC) and fluorescent-in situ hybridization (FISH) are stan...
Detection of human epidermal growth factor receptor 2 gene (HER2, also known as erbB2) expression is...
It seems that controversy is ever present regarding the optimal approach to testing for human epider...
The human epidermal growth factor receptor 2 gene (HER2) is amplified in approximately 15%–20% of al...
RATIONALE: Human epidermal growth factor receptor 2 (HER2) is a key driver of tumorigenesis, and ove...
Breast cancer patients who have a positive result for HER2 overexpression are commonly treated with ...
Knowledge of estrogen receptor (ER) and progesterone receptor (PR) status has been critical in the e...
Human epidermal growth factor receptor HER2/neu status is an important prognostic factor for breast ...
Over-expression of the human epidermal growth factor receptor-2 (HER2/neu) has been observed in many...
[[abstract]]Background: HER2 gene is amplified and/or overexpressed in approximate 15% to 20% of pri...
Objectives - Reliable assessment of estrogen, progesterone (ER and PR), and HER2 receptor status are...
Background: Optimization of workflow for breast cancer samples with equivocal human epidermal growth...
The assessment of ERa, PgR and HER2 status is routinely performed today to determine the endocrine r...
PURPOSE Decades of quality control efforts have raised the standards of immunohistochemistry (IHC...
Novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates have demonst...